Featured image: A clear glass bottle with a silver cap and a dropper is the main subject. AI-generated image; not a photograph of the reported event.
Fewer than 800 people in Scotland have received weight loss injections through the NHS. This number reflects a major gap between medical approval and real-world access. Source: bbc.co.uk.
What Happened
A BBC News investigation sent freedom of information requests to all nine Scottish health boards. The requests asked whether they prescribe GLP-1 injections specifically for weight loss.
Only six boards said they offer the treatment — all through small pilot programmes. The rest said they do not routinely prescribe for weight loss.
Some of these boards say they are reviewing access policies. They may introduce the drugs in the future if pilot results show safety and effectiveness.
Key Facts
- Mounjaro was approved for weight loss on the NHS in Scotland in 2023.
- Wegovy received full NHS approval for weight loss in 2024.
- Five health boards currently offer the drugs specifically for weight loss: NHS Forth Valley, NHS Borders, NHS Lothian, NHS Lanarkshire, NHS Western Isles, and NHS State Hospital.
- Patients must meet strict criteria — such as a BMI of 40 or above or serious medical conditions.
- Access is paused for new referrals in the NHS Forth Valley pilot to allow evaluation.
- At least 300,000 people access the drugs privately, according to Simple Online Pharmacy.
How the Treatments Work
GLP-1 injections like Mounjaro and Wegovy reduce hunger by sending signals to the brain. This makes patients feel full sooner and eat less.
These drugs were first approved for type 2 diabetes. Trials show they help people with obesity lose weight — especially when combined with lifestyle changes.
Studies show people who stop GLP-1 treatment regain weight four times faster than those who stop diet and exercise. Long-term support is key to keeping weight off.
Experts stress that weight loss is not just about medication. It requires healthy eating, physical activity, and ongoing health monitoring.
Personal Experience
Kathleen McClaughlin, 54, from Laurieston, was referred to the NHS Forth Valley programme by her gynaecologist. Surgery was unsafe due to her high BMI.
After years of failed weight loss attempts, she developed arthritis and mobility issues. She described her life as ‘vegetated’ — stuck in stagnation.
After starting the programme, she lost four stone — 13% of her body weight. Her physical and mental health improved.
She said, ‘I can’t believe I’m having the opportunity when so many others have to pay or can’t access it at all.’
The Forth Valley pilot serves 48 patients directly. Another 18 get the drugs through GP referrals. New referrals are paused for now.
Doctor Responses
Dr Mark Strachan, a diabetes specialist, called the current access ‘unacceptable.’ The NHS spends billions yearly treating obesity complications — not preventing them.
He can prescribe Mounjaro for type 2 diabetes, but not for weight loss — even on the same day. This inconsistency is ‘discriminatory,’ he said.
He warns that private prescriptions are rising sharply. This happens without health professional oversight — a rare situation in the NHS.
He says lower-income people are more likely to be obese. The private-NHS gap is worsening health inequalities.
Private Use and Access Gaps
Dr Jane Sehgal, a GP and health coach, supports patients using private channels. She says weight loss depends on sleep, stress, work-life balance, and relationships.
She stresses that medication alone isn’t enough. A full lifestyle plan is needed for lasting results.
Sabriena Clayton, 48, struggled with weight despite regular exercise. When her BMI rose above 30, she began private Mounjaro prescriptions.
She lost three stone. ‘At the start, it was like a switch turned off in my brain,’ she said. ‘I no longer think about food.’
Government Position
Public Health Minister Maree Todd says obesity medicines are one of several treatments — alongside diet and exercise.
She confirms that health boards decide on access. These decisions follow the National Consensus Statement on GLP-1s, which recommends a phased rollout based on BMI and medical conditions.
The government has not ordered a wide rollout. It insists access must be safe, fair, and financially sustainable.
Limitations and Open Questions
As of September 2026, only a small number of patients have received NHS weight loss injections.
Only six health boards offer the treatment — all through pilot schemes. No board has expanded access beyond these phases.
Many patients meet clinical criteria but still can’t access the drugs. This raises questions about policy barriers and equity.
Experts warn a rapid rollout could strain NHS finances. There is no clear plan to move from pilot to full access.
There is no public data on how many people are eligible or how many are referred. This limits transparency.
What to Watch Next
Health boards may expand access if pilot results show positive outcomes.
Tracking long-term weight maintenance will be key to future policy.
Any major change will depend on pilot results and pressure from doctors and patient groups.
Officials must balance cost, safety, and fairness. A more inclusive model is possible — but only with better data and clearer guidance.
More information on NHS access is available in the original BBC report: BBC News.
